에이프로젠바이오로직스 Stock: price and insider trades · South Korea

에이프로젠바이오로직스 belongs to the Health Care sector. Filings by its managers are published through DART (FSS). Over the twelve months to 2 November 2026, 25 filings were filed, from 8 insiders.

Open-market activity splits into 11 purchases totalling €7.6M and 11 sales totalling €1.2M; 2 insiders sit on the buying side and 8 insiders on the selling side. The totals exclude 20 filings filed without an amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. On the buying side, the filings list 1 major shareholder among the declarants. The largest single trade was a purchase of €7.6M by 에이프로젠, published on 30 March 2026, equal to 49.5% of the market capitalisation.

The most recent open-market purchase was published on 2 October 2026, 39 days ago. Typically, a trade is published a median of 7 days after it takes place. Until a filing is published, the market cannot know about the trade.

Compared with its exchange (2,655 companies, median 7 filings), a count of 25 filings is above the norm. Over the whole record (from 2022), the tally stands at 51 purchases and 26 sales.

In the same sector, recent insider purchases at Dynavox Group AB and UCB also feature in our signals. Every figure here comes from the filings published by DART (FSS) and describes the past, not future prices; it is not investment advice.